Reata Pharmaceuticals (NASDAQ:RETA) Stock Rating Lowered by National Securities

National Securities downgraded shares of Reata Pharmaceuticals (NASDAQ:RETA) from a buy rating to a neutral rating in a research report sent to investors on Wednesday, Briefing.com Automated Import reports.

A number of other brokerages have also weighed in on RETA. LADENBURG THALM/SH SH reaffirmed a positive rating and issued a $239.00 price target (up from $133.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, October 16th. Leerink Swann set a $230.00 price target on shares of Reata Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, October 15th. ValuEngine raised shares of Reata Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, November 1st. Citigroup raised their price target on shares of Reata Pharmaceuticals from $241.00 to $328.00 and gave the company a buy rating in a research note on Tuesday, November 12th. Finally, Stifel Nicolaus raised their price target on shares of Reata Pharmaceuticals from $135.00 to $210.00 and gave the company a buy rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $247.63.

Shares of NASDAQ RETA traded down $4.53 during mid-day trading on Wednesday, hitting $198.91. The stock had a trading volume of 877,400 shares, compared to its average volume of 719,663. Reata Pharmaceuticals has a twelve month low of $47.50 and a twelve month high of $217.47. The firm has a market cap of $6.12 billion, a PE ratio of -69.31 and a beta of 2.75. The company has a 50 day moving average of $152.87 and a two-hundred day moving average of $102.51.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.07). The company had revenue of $8.24 million during the quarter, compared to analysts’ expectations of $7.43 million. Reata Pharmaceuticals had a negative net margin of 398.84% and a negative return on equity of 3,282.73%. The company’s quarterly revenue was up 59.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.07) earnings per share. On average, equities research analysts expect that Reata Pharmaceuticals will post -5.35 EPS for the current fiscal year.

In other Reata Pharmaceuticals news, CAO Elaine Castellanos sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $200.00, for a total value of $800,000.00. Following the transaction, the chief accounting officer now directly owns 19,146 shares of the company’s stock, valued at approximately $3,829,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jason Douglas Wilson sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the vice president now directly owns 22,350 shares in the company, valued at $2,235,000. The disclosure for this sale can be found here. Insiders sold a total of 101,000 shares of company stock worth $10,661,430 over the last three months. Corporate insiders own 34.40% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Meadow Creek Investment Management LLC lifted its stake in Reata Pharmaceuticals by 71.4% in the 2nd quarter. Meadow Creek Investment Management LLC now owns 336 shares of the company’s stock worth $32,000 after purchasing an additional 140 shares in the last quarter. Glen Harbor Capital Management LLC lifted its stake in Reata Pharmaceuticals by 71.4% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 408 shares of the company’s stock worth $39,000 after purchasing an additional 170 shares in the last quarter. Invesco Ltd. lifted its stake in Reata Pharmaceuticals by 1.0% in the 2nd quarter. Invesco Ltd. now owns 18,750 shares of the company’s stock worth $1,769,000 after purchasing an additional 192 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Reata Pharmaceuticals by 25.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,240 shares of the company’s stock worth $100,000 after purchasing an additional 249 shares in the last quarter. Finally, M&T Bank Corp lifted its stake in Reata Pharmaceuticals by 7.7% in the 2nd quarter. M&T Bank Corp now owns 3,509 shares of the company’s stock worth $331,000 after purchasing an additional 250 shares in the last quarter. 58.24% of the stock is currently owned by institutional investors and hedge funds.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Recommended Story: What is the QQQ ETF?

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.